Chardan Capital analyst Keay Nakae reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $3.53.
According to TipRanks, Nakae is an analyst with an average return of -3.7% and a 33.56% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Arbutus Biopharma, and Synlogic.
Coya Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $18.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $8.00 and a one-year low of $3.21. Currently, Coya Therapeutics, Inc. has an average volume of 62.55K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Read More on COYA:
